Skip to main content

Table 2 Mediation analysis in 698 patients with rheumatoid arthritis from the Leiden Early Arthritis Clinic, with radiographic severity of joint damage over 7 years as the outcome variable

From: Studies on ageing and the severity of radiographic joint damage in rheumatoid arthritis

Step 1: effect of age on possible mediators

 

Effect (β)a

95 % CI

p value

SJC

1.00

1.00–1.01

0.11

TJC

1.00

1.00–1.01

0.55

Symptom duration

0.992

0.988–0.996

<0.001

CRP

1.016

1.011–1021

<0.001

RF

0.99

0.98–1.00

0.09

ACPA

0.98

0.97–0.99

<0.001

Step 2: effect of age on radiographic joint damage

 

Effect (β)

95 % CI

p value

Ageing

1.034

1.029–1.040

<0.001

Step 3: effect of age and possible mediator on radiographic joint damage

 

Effect (β)

95 % CI

p value

SJC

1.00

0.99–1.00

0.23

Ageing

1.035

1.029–1.040

<0.001

TJC

1.00

0.98–1.01

0.76

Ageing

1.037

1.030–1.044

<0.001

Symptom duration

1.003

1.002–1.005

<0.001

Ageing

1.035

1.029–1.040

<0.001

CRP

1.003

1.001–1.005

0.003

Ageing

1.033

1.027–1.038

<0.001

ACPA

1.37

1.16–1.60

<0.001

Ageing

1.035

1.030–1.040

<0.001

RF

1.30

1.10–1.52

0.002

Ageing

1.034

1.029–1.039

<0.001

  1. aThe effect size (β) of swollen joint count (SJC), tender joint count (TJC), symptom duration and C-reactive protein (CRP) reflect the increase per year increase of age. For example, the β for CRP is 1.016 this means that for every year increase in age there is 1.016-fold increase in CRP. A β of 0.992 indicates an increase 0.992- fold, hence actually a decrease. The effect size of anti-citrullinated protein antibody (ACPA) and rheumatoid factor (RF) reflect the odds ratio. Step 1, 2 and 3 of the mediation analyses are explained in Fig. 1. In step 1 a linear or logistic regression was used, in step 2 and 3 a multivariate normal regression analysis was used [27]. Also here the effects are per unit. For example, the β for age on joint damage is 1.034/year this means that for every year increase in age there is an increase of 3.4 % this is equal to an increase of 95.2 % every 20 years (1.034^20). All features (SJC, TJC, ACPA, RF, symptom duration, and age) were assessed at baseline